These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 21036133)
1. PCPP (poly[di(carboxylatophenoxy)-phosphazene]) microparticles co-encapsulating ovalbumin and CpG oligo-deoxynucleotides are potent enhancers of antigen specific Th1 immune responses in mice. Garlapati S; Eng NF; Wilson HL; Buchanan R; Mutwiri GK; Babiuk LA; Gerdts V Vaccine; 2010 Dec; 28(52):8306-14. PubMed ID: 21036133 [TBL] [Abstract][Full Text] [Related]
2. Co-administration of polyphosphazenes with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with Hepatitis B virus surface antigen. Mutwiri G; Benjamin P; Soita H; Babiuk LA Vaccine; 2008 May; 26(22):2680-8. PubMed ID: 18430493 [TBL] [Abstract][Full Text] [Related]
3. A novel triple adjuvant formulation promotes strong, Th1-biased immune responses and significant antigen retention at the site of injection. Wilson HL; Kovacs-Nolan J; Latimer L; Buchanan R; Gomis S; Babiuk L; van Drunen Littel-van den Hurk S Vaccine; 2010 Dec; 28(52):8288-99. PubMed ID: 20959153 [TBL] [Abstract][Full Text] [Related]
4. Co-delivery of ovalbumin and CpG motifs into microparticles protected sensitized mice from anaphylaxis. San Román B; Irache JM; Gómez S; Gamazo C; Espuelas S Int Arch Allergy Immunol; 2009; 149(2):111-8. PubMed ID: 19127067 [TBL] [Abstract][Full Text] [Related]
5. Co-encapsulation of an antigen and CpG oligonucleotides into PLGA microparticles by TROMS technology. San Román B; Irache JM; Gómez S; Tsapis N; Gamazo C; Espuelas MS Eur J Pharm Biopharm; 2008 Sep; 70(1):98-108. PubMed ID: 18501572 [TBL] [Abstract][Full Text] [Related]
6. Diaminosulfide based polymer microparticles as cancer vaccine delivery systems. Geary SM; Hu Q; Joshi VB; Bowden NB; Salem AK J Control Release; 2015 Dec; 220(Pt B):682-90. PubMed ID: 26359124 [TBL] [Abstract][Full Text] [Related]
7. Poly[di(sodium carboxylatoethylphenoxy)phosphazene] (PCEP) is a potent enhancer of mixed Th1/Th2 immune responses in mice immunized with influenza virus antigens. Mutwiri G; Benjamin P; Soita H; Townsend H; Yost R; Roberts B; Andrianov AK; Babiuk LA Vaccine; 2007 Jan; 25(7):1204-13. PubMed ID: 17140708 [TBL] [Abstract][Full Text] [Related]
8. Induction of a balanced Th1/Th2 immune responses by co-delivery of PLGA/ovalbumin nanospheres and CpG ODNs/PEI-SWCNT nanoparticles as TLR9 agonist in BALB/c mice. Ebrahimian M; Hashemi M; Maleki M; Abnous K; Hashemitabar G; Ramezani M; Haghparast A Int J Pharm; 2016 Dec; 515(1-2):708-720. PubMed ID: 27989827 [TBL] [Abstract][Full Text] [Related]
9. Time course study of the antigen-specific immune response to a PLGA microparticle vaccine formulation. Wang Q; Tan MT; Keegan BP; Barry MA; Heffernan MJ Biomaterials; 2014 Sep; 35(29):8385-93. PubMed ID: 24986256 [TBL] [Abstract][Full Text] [Related]
10. The STING activator c-di-AMP exerts superior adjuvant properties than the formulation poly(I:C)/CpG after subcutaneous vaccination with soluble protein antigen or DEC-205-mediated antigen targeting to dendritic cells. Volckmar J; Knop L; Stegemann-Koniszewski S; Schulze K; Ebensen T; Guzmán CA; Bruder D Vaccine; 2019 Aug; 37(35):4963-4974. PubMed ID: 31320219 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of poly[di(sodium carboxylatophenoxy)phosphazene] (PCPP) as mucosal adjuvant to induce protective immunity against respiratory pathogens. Shim DH; Ko HJ; Volker G; Potter AA; Mutwiri G; Babiuk LA; Kweon MN Vaccine; 2010 Mar; 28(11):2311-7. PubMed ID: 20060944 [TBL] [Abstract][Full Text] [Related]
12. Co-encapsulation of antigen and Toll-like receptor ligand in cationic liposomes affects the quality of the immune response in mice after intradermal vaccination. Bal SM; Hortensius S; Ding Z; Jiskoot W; Bouwstra JA Vaccine; 2011 Jan; 29(5):1045-52. PubMed ID: 21129393 [TBL] [Abstract][Full Text] [Related]
13. Potent antigen-specific immune responses stimulated by codelivery of CpG ODN and antigens in degradable microparticles. Zhang XQ; Dahle CE; Baman NK; Rich N; Weiner GJ; Salem AK J Immunother; 2007; 30(5):469-78. PubMed ID: 17589287 [TBL] [Abstract][Full Text] [Related]
14. Immunological responses after immunisation of mice with microparticles containing antigen and single stranded RNA (polyuridylic acid). Westwood A; Elvin SJ; Healey GD; Williamson ED; Eyles JE Vaccine; 2006 Mar; 24(11):1736-43. PubMed ID: 16278038 [TBL] [Abstract][Full Text] [Related]
15. Stable assemblies of cationic bilayer fragments and CpG oligonucleotide with enhanced immunoadjuvant activity in vivo. Rozenfeld JH; Silva SR; Ranéia PA; Faquim-Mauro E; Carmona-Ribeiro AM J Control Release; 2012 Jun; 160(2):367-73. PubMed ID: 22036878 [TBL] [Abstract][Full Text] [Related]
16. Poly[di(carboxylatophenoxy)phosphazene] (PCPP) is a potent immunoadjuvant for an influenza vaccine. Payne LG; Jenkins SA; Woods AL; Grund EM; Geribo WE; Loebelenz JR; Andrianov AK; Roberts BE Vaccine; 1998 Jan; 16(1):92-8. PubMed ID: 9607015 [TBL] [Abstract][Full Text] [Related]
17. A comparative study of the antigen-specific immune response induced by co-delivery of CpG ODN and antigen using fusion molecules or biodegradable microparticles. Zhang XQ; Dahle CE; Weiner GJ; Salem AK J Pharm Sci; 2007 Dec; 96(12):3283-92. PubMed ID: 17497736 [TBL] [Abstract][Full Text] [Related]
18. Formulation of bovine respiratory syncytial virus fusion protein with CpG oligodeoxynucleotide, cationic host defence peptide and polyphosphazene enhances humoral and cellular responses and induces a protective type 1 immune response in mice. Kovacs-Nolan J; Mapletoft JW; Lawman Z; Babiuk LA; van Drunen Littel-van den Hurk S J Gen Virol; 2009 Aug; 90(Pt 8):1892-1905. PubMed ID: 19386785 [TBL] [Abstract][Full Text] [Related]
19. Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles. Maloy KJ; Donachie AM; O'Hagan DT; Mowat AM Immunology; 1994 Apr; 81(4):661-7. PubMed ID: 7518802 [TBL] [Abstract][Full Text] [Related]
20. A protective allergy vaccine based on CpG- and protamine-containing PLGA microparticles. Martínez Gómez JM; Fischer S; Csaba N; Kündig TM; Merkle HP; Gander B; Johansen P Pharm Res; 2007 Oct; 24(10):1927-35. PubMed ID: 17541735 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]